CGC 729
Alternative Names: CGC-729Latest Information Update: 15 Oct 2025
At a glance
- Originator CureGenetics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 15 Oct 2025 CGC 729 is still in phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT06394622)
- 23 May 2024 Interim pharmacokinetics, efficacy and adverse events data from a phase-I trial in Solid tumours released by CureGenetics
- 11 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT06394622)